1. Academic Validation
  2. Delamanid: A new armor in combating drug-resistant tuberculosis

Delamanid: A new armor in combating drug-resistant tuberculosis

  • J Pharmacol Pharmacother. 2014 Jul;5(3):222-4. doi: 10.4103/0976-500X.136121.
Alphienes Stanley Xavier 1 Mageshwaran Lakshmanan 1
Affiliations

Affiliation

  • 1 Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
Abstract

Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.

Keywords

Delamanid; multidrug-resistant tuberculosis; mycolic acid inhibitor.

Figures
Products